206 related articles for article (PubMed ID: 21464155)
1. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
Pisters PWT; Blanke CD; von Mehren M; Picus J; Sirulnik A; Stealey E; Trent JC;
Ann Oncol; 2011 Nov; 22(11):2523-2529. PubMed ID: 21464155
[TBL] [Abstract][Full Text] [Related]
2. Management of recurrent gastrointestinal stromal tumors.
Winer JH; Raut CP
J Surg Oncol; 2011 Dec; 104(8):915-20. PubMed ID: 21337345
[TBL] [Abstract][Full Text] [Related]
3. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
4. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
7. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
9. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
10. Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Marano L; Boccardi V; Marrelli D; Roviello F
Eur J Surg Oncol; 2015 Jul; 41(7):814-22. PubMed ID: 25956211
[TBL] [Abstract][Full Text] [Related]
11. [Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
Nishida T; Wakasugi M; Ueshima S
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1330-5. PubMed ID: 22996768
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in therapy for gastrointestinal stromal tumors.
Maki RG
Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
[TBL] [Abstract][Full Text] [Related]
13. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then?
Nilsson B; Nilsson O; Ahlman H
Expert Opin Investig Drugs; 2009 Apr; 18(4):457-68. PubMed ID: 19335275
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
[TBL] [Abstract][Full Text] [Related]
16. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Nishida T; Yoshidome K; Tori M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
[No Abstract] [Full Text] [Related]
18. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
19. New paradigms in gastrointestinal stromal tumour management.
Blay JY
Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004
[TBL] [Abstract][Full Text] [Related]
20. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Le Cesne A; Blay JY; Reichardt P; Joensuu H
Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
